SEGMENT REPORTING AND FOREIGN OPERATIONS (Tables)

12 Months Ended

Dec. 31, 2025

Segment Reporting [Abstract]

Schedule of Long-lived Assets by Geographic Area

Our long-lived assets (which are comprised of our net property and equipment) by geographic area at December 31, 2025, 2024 and 2023, consisted of the following (in thousands):

	December 31, 2025		December 31, 2024		December 31, 2023
United States	$	300,593	$	271,734	$	273,105
Ireland		49,492		45,325		42,333
Other foreign countries		78,316		69,106		68,085
Total	$	428,401	$	386,165	$	383,523

Schedule of Segment Reporting Information, by Segment

Financial information relating to our reportable operating segments and reconciliations to the consolidated totals for the years ended December 31, 2025, 2024 and 2023, are as follows (in thousands):

	2025						2024						2023
	Cardiovascular		Endoscopy		Consolidated		Cardiovascular		Endoscopy		Consolidated		Cardiovascular		Endoscopy		Consolidated
Net sales	$	1,443,042	$	72,864	$	1,515,906	$	1,301,744	$	54,770	$	1,356,514	$	1,220,560	$	36,806	$	1,257,366
Cost of sales standard(1)		576,864		18,067				549,657		15,746				534,826		12,987
Cost of sales other(2)		173,686		9,019				140,948		6,830				125,388		293
Selling, general and administrative expenses		431,252		23,962				376,734		22,997				362,082		11,594
Research and development expenses		94,157		3,195				83,812		3,654				80,300		2,428
Other operating expenses(3)		950		34				443		—				3,524		—
Income from operations	$	166,133	$	18,587	$	184,720	$	150,150	$	5,543	$	155,693	$	114,440	$	9,504	$	123,944
Total other expense — net						(13,783)						(5,700)						(11,855)
Income before income taxes					$	170,937					$	149,993					$	112,089

(1) Cost of sales standard represents costs of goods sold measured at the internal standard cost for production of inventory. Inventory standard costs include material, labor and manufacturing overhead.

(2) Cost of sales other for all segments include amortization expense associated with our developed technology and license agreement intangible assets, freight and handling associated with shipments to customers, provisions based on estimated excess, slow moving and obsolete inventories, manufacturing and price variances, and royalties.

(3) Other operating expenses include impairment charges, contingent consideration expense related to the changes in fair value of contingent payments associated with acquisitions, and acquired in-process research and development expense.

Total depreciation and amortization by operating segment for the years ended December 31, 2025, 2024 and 2023, consisted of the following (in thousands):

	2025		2024		2023
Cardiovascular	$	113,785	$	97,749	$	88,960
Endoscopy		9,383		4,960		1,025
Total	$	123,168	$	102,709	$	89,985